Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. (31st December 2022)

• Record Type: Journal Article
• Authors: Yu, Yun; Zhang, Yu-Han; Liu, Liang; Yu, Ling-Ling; Li, Jun-Pei; Rao, Jing-an; Hu, Feng; Zhu, Ling-Juan; Bao, Hui-Hui; Cheng, Xiao-Shu
• Is Part Of: Adipocyte. Volume 11:Number 1(2022)
• Page Start: 1
• Page End: 10
• Publication Date: 2022-12-31
• Subjects: Obesity -- adipocyte -- tissue-specific gene expression -- drug-gene interaction -- bioinformatics -- biomarkers; Fat cells -- Periodicals; Adipocytes -- Periodicals; 611.018276
• DOI: 10.1080/21623945.2021.2013406
• Languages: English
• ISSNs: 2162-3945

Abstract

ABSTRACT: Obesity is a complex medical condition that affects multiple organs in the body. However, the underlying mechanisms of obesity, as well as its treatment, are largely unexplored . The focus of this research was to use bioinformatics to discover possible treatment targets for obesity. To begin, the GSE133099 database was used to identify 364 differentially expressed genes (DEGs). Then, DEGs were subjected to tissue-specific analyses and enrichment analyses, followed by the creation of a protein-protein interaction (PPI) network and generation of a drug-gene interaction database to screen key genes and potential future drugs targeting obesity. Findings have illustrated that the tissue-specific expression of neurologic markers varied significantly (34.7%, 52/150). Among these genes, Lep, ApoE, Fyn, and FN1 were the key genes observed in the adipocyte samples from obese patients relative to the controls. Furthermore, nine potential therapeutic drugs (dasatinib, ocriplasmin, risperidone, gemfibrozil, ritonavir, fluvastatin, pravastatin, warfarin, atorvastatin) that target the key genes were also screened and selected. To conclude the key genes discovered (Lep, ApoE, Fyn, and FN1), as well as 9 candidate drugs, could be used as therapeutic targets in treating obesity.